Adjuvant Nivolumab in Resected Lung Cancers- (ANVIL)- A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

IRB/UVA Tracking #
19055
Contact
Gracie Hockenberry
Contact Email
Contact Phone
1.434.297.7784
Phase
III
Primary purpose
Treatment
Cancer PI
Ryan Gentzler
Status
OPEN TO ACCRUAL
Ages
Adult